Skip to main content
. 2022 Dec 9;13:1052937. doi: 10.3389/fimmu.2022.1052937

Table 1.

Baseline characteristics of patients.

Characteristics All patients N = 85, N (%) ICI+Lenva N = 58, N (%) ICI+Others N = 27, N (%) P - value
Medical center 0.183
 PUMCH 63 (74.1) 40 (69.0) 23 (85.2)
 PLAGH 22 (25.9) 18 (31.0) 4 (14.8)
Age 1
 < 65 67 (78.8) 46 (79.3) 21 (77.8)
 ≥ 65 18 (21.2) 12 (20.7) 6 (22.2)
Sex 0.508
 Female 12 (14.1) 7 (12.1) 5 (18.5)
 Male 73 (85.9) 51 (87.9) 22 (81.5)
Viral Hepatitis 0.804
 HBV 66 (77.7) 46 (79.3) 20 (74.1)
 HCV 3 (3.5) 2 (3.5) 1 (3.7)
 NBNC 16 (18.8) 10 (17.2) 6 (22.2)
Alcohol consumption 0.791
 No 63 (74.1) 42 (72.4) 21 (77.8)
 Yes 22 (25.9) 16 (27.6) 6 (22.2)
ECOG 0.35
 0 32 (37.7) 23 (39.7) 9 (33.3)
 1 46 (54.1) 32 (55.2) 14 (51.9)
 2 7 (8.2) 3 (5.2) 4 (14.8)
Child–Pugh 1
 A 61 (71.8) 42 (72.4) 19 (70.4)
 B 24 (28.2) 16 (27.6) 8 (29.6)
AFP (ng/ml) 1
 < 400 53 (62.3) 36 (62.1) 17 (63.0)
 ≥ 400 32 (37.7) 22 (37.9) 10 (37.0)
Tumor number 0.660
 1 6 (7.1) 5 (8.6) 1 (3.7)
 ≥ 2 79 (92.9) 53 (91.4) 26 (96.3)
Tumor size 0.625
 < 5 cm 28 (32.9) 18 (31.0) 10 (37.0)
 ≥ 5 cm 57 (67.1) 40 (69.0) 17 (63.0)
Macrovascular invasion 0.168
 No 47 (55.3) 29 (50.0) 18 (66.7)
 Yes 38 (44.7) 29 (50.0) 9 (33.3)
Extrahepatic metastasis 0.81
 No 31 (36.5) 22 (37.9) 9 (33.3)
 Yes 54 (63.5) 36 (62.1) 18 (66.7)
BCLC staging 1
 B 9 (10.6) 6 (10.3) 3 (11.1)
 C 76 (89.4) 52 (89.7) 24 (88.9)
Previous systemic treatment 0.477
 No 55 (64.7) 39 (67.2) 16 (59.3)
 Yes 30 (35.3) 19 (32.8) 11 (40.7)
Previous locoregional treatment 1
 No 12 (14.1) 8 (13.8) 4 (14.8)
 Yes 73 (85.9) 50 (86.2) 23 (85.2)

PUMCH, Peking Union Medical College Hospital; PLAGH, Chinese Peoples’ Liberation Army General Hospital; HBV, hepatitis B virus; HCV, hepatitis C virus; NBNC, no HBV or HCV infection; AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer.